@article {8055,
	title = {Reverse of the Differential Uptake Intensity of Tc-99m MIBI and Tc-99m V-DMSA By Multiple Myeloma Lesions in Response to Therapy},
	journal = {Clinical Nuclear Medicine},
	volume = {28},
	year = {2003},
	note = {Cited By :11Export Date: 21 February 2017},
	month = {2003},
	pages = {631 - 635},
	abstract = {Purpose: The objective of this study was to compare the uptake changes of Tc-99m 2-methoxy isobutyl isonitrile (MIBI) and Tc-99m pentavalent dimercaptosuccinic acid (V-DMSA) in multiple myeloma (MM) lesions in response to high-dose chemotherapy (HDC). Materials and Methods: The authors compared Tc-99m MIBI and Tc-99m V-DMSA scans before and after HDC in a patient with focal MM lesions without amyloidosis who had received previous standard chemotherapy as well. Results: HDC had the effect of eliminating all Tc-99m MIBI uptake in the lesions. Tc-99m V-DMSA uptake was increased in lesions presenting significant initial Tc-99m MIBI uptake. In 1 particular lesion that demonstrated this phenomenon, magnetic resonance showed necrosis of the area of MM. Conclusion: The authors consider that the effect of increasing Tc-99m V-DMSA uptake in the absence of an increase in viable plasma cells possibly reflects the treatment-generated inflammatory and fibrotic changes and not necessarily viable tumor tissue. Exclusive focal Tc-99m V-DMSA uptake in this clinical setting could be considered as a sign of effectively treated lesions and not a sign of deterioration.},
	keywords = {multiple myeloma, Tc-99m sestamibi, Tc-99m V-DMSA},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-1442309452\&doi=10.1097\%2f00003072-200308000-00001\&partnerID=40\&md5=e9497ddb215d46b03afb6172db65c1fb},
	author = {Athanasoulis, T. and Koutsikos, J. and Moulopoulos, L.A. and Tsiouris, S. and Dimopoulos, M.A. and Zerva, C.}
}
